dc.contributor
Institut Català de la Salut
dc.contributor
[Vitiello PP, Bardelli A] Department of Oncology, University of Torino, Italy. IFOM ETS – The AIRC Institute of Molecular Oncology, Milan, Italy. [Saoudi González N] IFOM ETS – The AIRC Institute of Molecular Oncology, Milan, Italy. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Vitiello, Pietro Paolo
dc.contributor.author
BARDELLI, Alberto
dc.contributor.author
Saoudi Gonzalez, Nadia
dc.date.accessioned
2025-10-25T05:39:12Z
dc.date.available
2025-10-25T05:39:12Z
dc.date.issued
2025-03-06T13:44:57Z
dc.date.issued
2025-03-06T13:44:57Z
dc.identifier
Vitiello PP, Saoudi González N, Bardelli A. When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer. Mol Oncol. 2025 Feb;19(2):267–70.
dc.identifier
http://hdl.handle.net/11351/12702
dc.identifier
10.1002/1878-0261.13754
dc.identifier
001344720400001
dc.identifier.uri
http://hdl.handle.net/11351/12702
dc.description.abstract
Colorectal cancer; Drug resistance; Precision medicine
dc.description.abstract
Cáncer colorrectal; Resistencia a medicamentos; Medicina de precisión
dc.description.abstract
Càncer colorectal; Resistència a medicaments; Medicina de precisió
dc.description.abstract
The discovery of growth factors and their involvement in cancer represents the foundation of precision oncology. The preclinical and clinical development of agents targeting epidermal growth factor receptor (EGFR) in colorectal cancer (CRC) were accompanied by big hype and hopes, though the clinical testing of such agents clashed with intrinsic and acquired resistance, greatly limiting their therapeutic value. However, a better understanding of the biology of the EGFR signaling pathway in CRC, coupled with the development of liquid biopsy methodologies to study cancer evolution in real time, fostered the clinical refinement of anti-EGFR treatment in CRC. Such a workflow, based on the co-evolution of biology knowledge and clinical development, allowed to couple the discovery of relevant therapy resistance mechanisms to the development of strategies to bypass this resistance. A broader application of this paradigm could prove successful and create an effective shortcut between the bench and the bedside for treatment strategies other than targeted therapy.
dc.description.abstract
AB is supported by: FONDAZIONE AIRC under 5 per Mille 2018 – ID. 21091 program – P.I. Alberto Bardelli; AIRC under IG 2023 – ID. 28922 project – P.I. Alberto Bardelli; International Accelerator Award, ACRCelerate, jointly funded by Cancer Research UK (A26825 and A28223), FC AECC (GEACC18004TAB) and AIRC (22795); IMI contract no. 101007937 PERSIST-SEQ; European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (TARGET, grant agreement no. 101020342) – P.I. Alberto Bardelli; PRIN (Progetti di Rilevante Interesse Nazionale) no. 2022CHB9BA – P.I. Alberto Bardelli. NSG is supported by a European Society for Medical Oncology (ESMO) Translational Research Fellowship. Any views, opinions, findings, conclusions, or recommendations expressed in this material are those solely of the authors and do not necessarily reflect those of ESMO. Images were generated with biorender.com.
dc.format
application/pdf
dc.relation
Molecular Oncology;19(2)
dc.relation
https://doi.org/10.1002/1878-0261.13754
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Medicaments antineoplàstics - Ús terapèutic
dc.subject
Recte - Càncer - Tractament
dc.subject
Còlon - Càncer - Tractament
dc.subject
Resistència als medicaments
dc.subject
Biologia molecular
dc.subject
Farmacologia molecular
dc.subject
Factor de creixement epidèrmic - Receptors
dc.subject
CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Tyrosine Kinases::Receptor Protein-Tyrosine Kinases::ErbB Receptors
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
dc.subject
PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
DISCIPLINES AND OCCUPATIONS::Natural Science Disciplines::Biological Science Disciplines::Biochemistry::Molecular Biology
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::transferasas::fosfotransferasas::fosfotransferasas (grupo alcohol aceptor)::proteína cinasas::proteína-tirosina cinasas::receptores proteína-tirosina cinasas::receptores ErbB
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
dc.subject
FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos
dc.subject
DISCIPLINAS Y OCUPACIONES::disciplinas de las ciencias naturales::disciplinas de las ciencias biológicas::bioquímica::biología molecular
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.title
When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
